Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zandra Walton

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Cancer Research|March 29, 2014
Failure to induce apoptosis via BCL-2 family proteins underlies lack of efficacy of combined MEK and PI3K inhibitors for KRAS-mutant lung cancersAaron N Hata, Alan Yeo, Anthony C Faber, et al.
Cancer Research|March 11, 2010
An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activationBirgit Schoeberl, Anthony C Faber, Danan Li, et al.
Cell Cycle (Georgetown, Tex.)|August 9, 2011
Characterization of the cell of origin for small cell lung cancerKwon-Sik Park, Mei-Chih Liang, David M Raiser, et al.
Cancer Cell|September 13, 2011
Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumorsThomas De Raedt, Zandra Walton, Jessica L Yecies, et al.
Cancer Cell|May 6, 2014
Loss of Lkb1 and Pten leads to lung squamous cell carcinoma with elevated PD-L1 expressionChunxiao Xu, Christine M Fillmore, Shohei Koyama, et al.
Nature|March 20, 2012
A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic responseZhao Chen, Katherine Cheng, Zandra Walton, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Cancer Research|March 29, 2014
Failure to induce apoptosis via BCL-2 family proteins underlies lack of efficacy of combined MEK and PI3K inhibitors for KRAS-mutant lung cancersAaron N Hata, Alan Yeo, Anthony C Faber, et al.
Cancer Research|March 11, 2010
An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activationBirgit Schoeberl, Anthony C Faber, Danan Li, et al.
Cell Cycle (Georgetown, Tex.)|August 9, 2011
Characterization of the cell of origin for small cell lung cancerKwon-Sik Park, Mei-Chih Liang, David M Raiser, et al.
Cancer Cell|September 13, 2011
Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumorsThomas De Raedt, Zandra Walton, Jessica L Yecies, et al.
Cancer Cell|May 6, 2014
Loss of Lkb1 and Pten leads to lung squamous cell carcinoma with elevated PD-L1 expressionChunxiao Xu, Christine M Fillmore, Shohei Koyama, et al.
Nature|March 20, 2012
A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic responseZhao Chen, Katherine Cheng, Zandra Walton, et al.
Pageof 1